According to Vision Research Reports, the global gynecology drugs market size is expected to hit around US$ 85.81 billion by 2027 and projected to expand at a CAGR of 5.7% during forecast period 2020 to 2027.
The global gynecology drugs market is anticipated to be driven by rising incidence and prevalence rate of gynecological diseases during the forecast period. The gynecology drugs market in Asia Pacific is expected to expand at a high CAGR of 6.5%, due to the high prevalence of diseases, improvements in the health care sector, and increasing focus of key players on business expansion.
Worldwide increase in the prevalence of gynecological disorders
Gynecologic disorders affect the female reproductive system. The most common symptoms of gynecologic disorders include pelvic pain, vaginal itching, vaginal discharge, abnormal vaginal bleeding, and breast pain and lumps. The significance and severity of these symptoms often depend on age, as these symptoms may be related to hormonal changes that occur with aging.
Among other prominent gynecological diseases, sexually transmitted disease (STD) is the most common and critical – the most common STD among women is pelvic inflammatory disease. In the U.S. alone, more than one million women suffer from this disorder in their lifetime, followed by chlamydia – a sexually transmitted infection of the vagina, which, if left untreated, develops into pelvic inflammatory disease. Gynecological disorders may or may not be related to the menstrual cycle, which prominently include menstrual cramps and endometriosis (abnormally located patches of tissue that is normally located only in the lining of the uterus). Additionally, gynecological cancers are also common among women around the globe. Endometrial cancer and ovarian cancer are highly common among women. Therefore, increase in the prevalence of the conditions mentioned above, are likely to increase the uptake of gynecology drugs.
Rise in number of women facing menopausal conditions
Rise in number of women facing menopausal condition is a major factor that is expected to drive the market during the forecast period. Menopause is defined as permanent cessation of menstruation, resulting from loss of activity of ovarian follicles. In a majority of women, menopause is a natural event occurring at the age of around 51.3 years. The number of women entering menopausal condition is increasing year on year, due to unhealthy lifestyle and different environmental factors. In Canada, presently, over five million women aged between 45 and 65 have either gone through menopause or are expected to soon go through menopause. The average age of menopause in Canada is 51 years. Moreover, according to the Society of Obstetricians & Gynecologists of Canada, around 80% women claim to suffer from at least one menopausal symptom including mood swings, irritability, interrupted sleep, hot flashes, and vaginal dryness. Incidence of menopausal vasomotor symptoms has risen significantly in the last few years, which in turn drives the global gynecology drugs market.
The global gynecology drugs market has been segmented based on therapeutics, indication, distribution channel, and region. Furthermore, in terms of therapeutics, the market has been divided into hormonal therapy and non-hormonal therapy. The non-hormonal therapy segment is likely to account for a leading share of the global market during the forecast period owing to the effectiveness of the products, rising adoption of these products, and new product development. Decreasing use of hormonal products due to the risk of breast cancer has boosted the demand for non-hormonal pharmaceutical products. In terms of indication, the market has been classified into gynecology cancers, endometriosis, female infertility, menopausal disorder, gynecology infections, polycystic ovary syndrome, contraception (birth control), and others. In terms of distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is projected to expand at a significant CAGR during the forecast period, owing to the ease of using online pharmacy and rise in the number of internet users.
Huge patient base of gynecology disease in Asia Pacific to create opportunities in market
In terms of region, the global gynecology devices market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to hold a leading share of the global market during the forecast period, owing to high rate of adoption of technological advanced products, presence of key players, and high health care expenditure. Europe is anticipated to account for a significant share of the global market between 2020 and 2027. Increase in incidence of gynecological diseases is expected to fuel the market in the region during the forecast period. The market in Asia Pacific is likely to witness robust expansion during the forecast period, due to surge in health care expenditure. Moreover, increasing focus of key players on expansion in Asia Pacific, large untapped population in the region, and rising awareness about health care drive the gynecology drugs market in Asia Pacific. The gynecology drugs market in Latin America and Middle East & Africa is anticipated to expand at a steady pace from 2020 to 2027.
The report analyzes and forecasts the gynecological devices market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2020 to 2027. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of gynecological devices, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major gynecological devices companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of gynecological devices upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of gynecological devices and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global gynecological devices market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the gynecological devices market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of gynecological devices market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles major players in the global gynecology drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players in the global gynecology drugs market are Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc, Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Allergan Plc, and Bayer AG.
Report Segmentation:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Gynecology Drugs Market: Market Snapshot
4. Market Overview
4.1. Global Gynecology Drugs Market: Product Overview
4.2. Global Gynecology Drugs Market: Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gynecology Drugs Market Revenue Projections, 2016–2026
4.5. Porter’s Five Forces Analysis
4.6. Global Gynecology Drugs Market Outlook
5. Market Outlook
5.1. Regulatory Scenario
5.2. Disease Prevalence
5.3. Pipeline Analysis
6. Global Gynecology Drugs Market Analysis, by Therapeutics
6.1. Key Findings
6.2. Introduction
6.3. Global Gynecology Drugs Market Value Share, by Therapeutics
6.4. Global Gynecology Drugs Market Value Forecast, by Therapeutics
6.4.1. Hormonal Therapy
6.4.1.1. Estrogen Therapy
6.4.1.2. Progestin Therapy
6.4.1.3. Combination Therapy
6.4.1.4. Thyroid Replacement Therapy
6.4.1.5. Parathyroid Hormone Therapy
6.4.1.6. Others
6.4.2. Non-hormonal Therapy
6.4.2.1. Anti-Infective Agents
6.4.2.2. Anti-neoplastic Agents
6.4.2.3. Anti-inflammatory Agents
6.4.2.4. Others
6.5. Global Gynecology Drugs Market Analysis, by Therapeutics
6.6. Global Gynecology Drugs Market Attractiveness Analysis, by Therapeutics
7. Global Gynecology Drugs Market Analysis, by Indication
7.1. Key Findings
7.2. Introduction
7.3. Global Gynecology Drugs Market Value Share, by Indication
7.4. Global Gynecology Drugs Market Value Forecast, by Indication
7.4.1.1. Gynecology Cancers
7.4.1.2. Endometriosis
7.4.1.3. Female Infertility
7.4.1.4. Menopausal Disorder
7.4.1.5. Gynecology Infections
7.4.1.6. Polycystic Ovary Syndrome
7.4.1.7. Contraception (Birth Control)
7.4.1.8. Others
7.5. Global Gynecology Drugs Market Analysis, by Indication
7.6. Global Gynecology Drugs Market Attractiveness Analysis, by Indication
8. Global Gynecology Drugs Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Global Gynecology Drugs Market Value Share, by Distribution Channel
8.4. Global Gynecology Drugs Market Value Forecast, by Distribution Channel
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Online Pharmacies
8.5. Global Gynecology Drugs Market Analysis, by Distribution Channel
8.6. Global Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel
9. Global Gynecology Drugs Market Analysis, by Region
9.1. Global Gynecology Drugs Market Scenario, by Country
9.2. Global Gynecology Drugs Market Value Share, by Region
9.3. Global Gynecology Drugs Market Value Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Global Gynecology Drugs Market Attractiveness Analysis, by Region
10. North America Gynecology Drugs Market Analysis
10.1. Key Findings
10.2. North America Gynecology Drugs Market Overview
10.3. North America Gynecology Drugs Market Value Share, by Country
10.4. North America Gynecology Drugs Market Forecast, by Country
10.4.1. U.S.
10.4.2. Canada
10.5. North America Gynecology Drugs Market Value Share Analysis, by Therapeutics
10.6. North America Gynecology Drugs Market Forecast, by Therapeutics
10.6.1. Hormonal Therapy
10.6.1.1. Estrogen Therapy
10.6.1.2. Progestin Therapy
10.6.1.3. Combination Therapy
10.6.1.4. Thyroid Replacement Therapy
10.6.1.5. Parathyroid Hormone Therapy
10.6.1.6. Others
10.6.2. Non-hormonal Therapy
10.6.2.1. Anti-Infective Agents
10.6.2.2. Anti-neoplastic Agents
10.6.2.3. Anti-inflammatory Agents
10.6.2.4. Others
10.7. North America Gynecology Drugs Market Value Share Analysis, by Indication
10.8. North America Gynecology Drugs Market Forecast, by Indication
10.8.1. Gynecology Cancers
10.8.2. Endometriosis
10.8.3. Female Infertility
10.8.4. Menopausal Disorder
10.8.5. Gynecology Infections
10.8.6. Polycystic Ovary Syndrome
10.8.7. Contraception (Birth Control)
10.8.8. Others
10.9. North America Gynecology Drugs Market Value Share Analysis, by Distribution Channel
10.10. North America Gynecology Drugs Market Forecast, by Distribution Channel
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Online Pharmacies
10.11. North America Gynecology Drugs Market Attractiveness Analysis
11. Europe Gynecology Drugs Market Analysis
11.1. Key Findings
11.2. Europe Gynecology Drugs Market Overview
11.3. Europe Gynecology Drugs Market Value Share, by Country/Sub-region
11.4. Europe Gynecology Drugs Market Forecast, by Country/Sub-region
11.4.1. UK
11.4.2. Germany
11.4.3. France
11.4.4. Italy
11.4.5. Spain
11.4.6. Rest of Europe
11.5. Europe Gynecology Drugs Market Value Share Analysis, by Therapeutics
11.6. Europe Gynecology Drugs Market Forecast, by Therapeutics
11.6.1. Hormonal Therapy
11.6.1.1. Estrogen Therapy
11.6.1.2. Progestin Therapy
11.6.1.3. Combination Therapy
11.6.1.4. Thyroid Replacement Therapy
11.6.1.5. Parathyroid Hormone Therapy
11.6.1.6. Others
11.6.2. Non-hormonal Therapy
11.6.2.1. Anti-Infective Agents
11.6.2.2. Anti-neoplastic Agents
11.6.2.3. Anti-inflammatory Agents
11.6.2.4. Others
11.7. Europe Gynecology Drugs Market Value Share Analysis, by Indication
11.8. Europe Gynecology Drugs Market Forecast, by Indication
11.8.1. Gynecology Cancers
11.8.2. Endometriosis
11.8.3. Female Infertility
11.8.4. Menopausal Disorder
11.8.5. Gynecology Infections
11.8.6. Polycystic Ovary Syndrome
11.8.7. Contraception (Birth Control)
11.8.8. Others
11.9. Europe Gynecology Drugs Market Value Share Analysis, by Distribution Channel
11.10. Europe Gynecology Drugs Market Forecast, by Distribution Channel
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Online Pharmacies
11.11. Europe Gynecology Drugs Market Attractiveness Analysis
12. Asia Pacific Gynecology Drugs Market Analysis
12.1. Key Findings
12.2. Asia Pacific Gynecology Drugs Market Overview
12.3. Asia Pacific Gynecology Drugs Market Value Share, by Country/Sub-region
12.4. Asia Pacific Gynecology Drugs Market Forecast, by Country/Sub-region
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Therapeutics
12.6. Asia Pacific Gynecology Drugs Market Forecast, by Therapeutics
12.6.1. Hormonal Therapy
12.6.1.1. Estrogen Therapy
12.6.1.2. Progestin Therapy
12.6.1.3. Combination Therapy
12.6.1.4. Thyroid Replacement Therapy
12.6.1.5. Parathyroid Hormone Therapy
12.6.1.6. Others
12.6.2. Non-hormonal Therapy
12.6.2.1. Anti-Infective Agents
12.6.2.2. Anti-neoplastic Agents
12.6.2.3. Anti-inflammatory Agents
12.6.2.4. Others
12.7. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Indication
12.8. Asia Pacific Gynecology Drugs Market Forecast, by Indication
12.8.1. Gynecology Cancers
12.8.2. Endometriosis
12.8.3. Female Infertility
12.8.4. Menopausal Disorder
12.8.5. Gynecology Infections
12.8.6. Polycystic Ovary Syndrome
12.8.7. Contraception (Birth Control)
12.8.8. Others
12.9. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Distribution Channel
12.10. Asia Pacific Gynecology Drugs Market Forecast, by Distribution Channel
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Pharmacies
12.11. Asia Pacific Gynecology Drugs Market Attractiveness Analysis
13. Latin America Gynecology Drugs Market Analysis
13.1. Key Findings
13.2. Latin America Gynecology Drugs Market Overview
13.3. Latin America Gynecology Drugs Market Value Share, by Country/Sub-region
13.4. Latin America Gynecology Drugs Market Forecast, by Country/Sub-region
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Gynecology Drugs Market Value Share Analysis, by Therapeutics
13.6. Latin America Gynecology Drugs Market Forecast, by Therapeutics
13.6.1. Hormonal Therapy
13.6.1.1. Estrogen Therapy
13.6.1.2. Progestin Therapy
13.6.1.3. Combination Therapy
13.6.1.4. Thyroid Replacement Therapy
13.6.1.5. Parathyroid Hormone Therapy
13.6.1.6. Others
13.6.2. Non-hormonal Therapy
13.6.2.1. Anti-Infective Agents
13.6.2.2. Anti-neoplastic Agents
13.6.2.3. Anti-inflammatory Agents
13.6.2.4. Others
13.7. Latin America Gynecology Drugs Market Value Share Analysis, by Indication
13.8. Latin America Gynecology Drugs Market Forecast, by Indication
13.8.1. Gynecology Cancers
13.8.2. Endometriosis
13.8.3. Female Infertility
13.8.4. Menopausal Disorder
13.8.5. Gynecology Infections
13.8.6. Polycystic Ovary Syndrome
13.8.7. Contraception (Birth Control)
13.8.8. Others
13.9. Latin America Gynecology Drugs Market Value Share Analysis, by Distribution Channel
13.10. Latin America Gynecology Drugs Market Forecast, by Distribution Channel
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Pharmacies
13.11. Latin America Gynecology Drugs Market Attractiveness Analysis
14. Middle East & Africa Gynecology Drugs Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Gynecology Drugs Market Overview
14.3. Middle East & Africa Gynecology Drugs Market Value Share, by Country/Sub-region
14.4. Middle East & Africa Gynecology Drugs Market Forecast, by Country/Sub-region
14.4.1. GCC
14.4.2. South Africa
14.4.3. Rest of MEA
14.5. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Therapeutics
14.6. Middle East & Africa Gynecology Drugs Market Forecast, by Therapeutics
14.6.1. Hormonal Therapy
14.6.1.1. Estrogen Therapy
14.6.1.2. Progestin Therapy
14.6.1.3. Combination Therapy
14.6.1.4. Thyroid Replacement Therapy
14.6.1.5. Parathyroid Hormone Therapy
14.6.1.6. Others
14.6.2. Non-hormonal Therapy
14.6.2.1. Anti-Infective Agents
14.6.2.2. Anti-neoplastic Agents
14.6.2.3. Anti-inflammatory Agents
14.6.2.4. Others
14.7. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Indication
14.8. Middle East & Africa Gynecology Drugs Market Forecast, by Indication
14.8.1. Gynecology Cancers
14.8.2. Endometriosis
14.8.3. Female Infertility
14.8.4. Menopausal Disorder
14.8.5. Gynecology Infections
14.8.6. Polycystic Ovary Syndrome
14.8.7. Contraception (Birth Control)
14.8.8. Others
14.9. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Distribution Channel
14.10. Middle East & Africa Gynecology Drugs Market Forecast, by Distribution Channel
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Pharmacies
14.11. Middle East & Africa Gynecology Drugs Market Attractiveness Analysis
15. Competition Landscape
15.1. Gynecology Drugs Market Share Analysis, by Company, 2017
15.2. Competition Matrix
15.3. Company Profiles
15.3.1. Allergan plc.
15.3.1.1. Company Details
15.3.1.2. Business Overview
15.3.1.3. Financial Overview
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Amgen Inc.
15.3.2.1. Company Details
15.3.2.2. Business Overview
15.3.2.3. Financial Overview
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Bayer AG
15.3.3.1. Company Details
15.3.3.2. Business Overview
15.3.3.3. Financial Overview
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Details
15.3.4.2. Business Overview
15.3.4.3. Financial Overview
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Pfizer Inc.
15.3.5.1. Company Details
15.3.5.2. Business Overview
15.3.5.3. Financial Overview
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Eli Lilly Company
15.3.6.1. Company Details
15.3.6.2. Business Overview
15.3.6.3. Financial Overview
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1. Company Details
15.3.7.2. Business Overview
15.3.7.3. Financial Overview
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. AstraZeneca
15.3.8.1. Company Details
15.3.8.2. Business Overview
15.3.8.3. Financial Overview
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers